305 related articles for article (PubMed ID: 23836291)
1. First-trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell-free DNA.
Johnson J; Pastuck M; Metcalfe A; Connors G; Krause R; Wilson D; Cuckle H
Prenat Diagn; 2013 Nov; 33(11):1044-9. PubMed ID: 23836291
[TBL] [Abstract][Full Text] [Related]
2. First trimester screening for Down syndrome using nuchal translucency, maternal serum pregnancy-associated plasma protein A, free-β human chorionic gonadotrophin, placental growth factor, and α-fetoprotein.
Huang T; Dennis A; Meschino WS; Rashid S; Mak-Tam E; Cuckle H
Prenat Diagn; 2015 Jul; 35(7):709-16. PubMed ID: 25846403
[TBL] [Abstract][Full Text] [Related]
3. Modeling Down syndrome screening performance using first-trimester serum markers.
Koster MP; Wortelboer EJ; Stoutenbeek P; Visser GH; Schielen PC
Ultrasound Obstet Gynecol; 2011 Aug; 38(2):134-9. PubMed ID: 21800388
[TBL] [Abstract][Full Text] [Related]
4. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
[TBL] [Abstract][Full Text] [Related]
5. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
[TBL] [Abstract][Full Text] [Related]
6. First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Hoopmann M; Abele H; Alkier R; Lüthgens K
Ultrasound Obstet Gynecol; 2012 Nov; 40(5):530-5. PubMed ID: 22611005
[TBL] [Abstract][Full Text] [Related]
7. First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH; Wright D; Poon LC; Syngelaki A; Gil MM
Ultrasound Obstet Gynecol; 2013 Jul; 42(1):41-50. PubMed ID: 23744626
[TBL] [Abstract][Full Text] [Related]
8. ADAM 12 as a first-trimester maternal serum marker in screening for Down syndrome.
Laigaard J; Spencer K; Christiansen M; Cowans NJ; Larsen SO; Pedersen BN; Wewer UM
Prenat Diagn; 2006 Oct; 26(10):973-9. PubMed ID: 16892462
[TBL] [Abstract][Full Text] [Related]
9. First-trimester or second-trimester screening, or both, for Down's syndrome.
Malone FD; Canick JA; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Dukes K; Bianchi DW; Rudnicka AR; Hackshaw AK; Lambert-Messerlian G; Wald NJ; D'Alton ME;
N Engl J Med; 2005 Nov; 353(19):2001-11. PubMed ID: 16282175
[TBL] [Abstract][Full Text] [Related]
10. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
[TBL] [Abstract][Full Text] [Related]
11. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
12. Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
Borenstein M; Persico N; Kagan KO; Gazzoni A; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Jul; 32(1):5-11. PubMed ID: 18512854
[TBL] [Abstract][Full Text] [Related]
13. First-trimester combined screening for trisomy 21 at 7-14 weeks' gestation.
Wright D; Spencer K; Kagan K K; Tørring N; Petersen OB; Christou A; Kallikas J; Nicolaides KH
Ultrasound Obstet Gynecol; 2010 Oct; 36(4):404-11. PubMed ID: 20658511
[TBL] [Abstract][Full Text] [Related]
14. Combining fetal nuchal fold thickness with second-trimester biochemistry to screen for trisomy 21.
Borrell A; Mercade I; Casals E; Borobio V; Seres A; Soler A; Fortuny A; Cuckle H
Ultrasound Obstet Gynecol; 2007 Dec; 30(7):941-5. PubMed ID: 18000942
[TBL] [Abstract][Full Text] [Related]
15. SURUSS in perspective.
Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
[TBL] [Abstract][Full Text] [Related]
16. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
[TBL] [Abstract][Full Text] [Related]
17. First-trimester combined ultrasound and biochemical screening for Down syndrome in routine clinical practice.
Stenhouse EJ; Crossley JA; Aitken DA; Brogan K; Cameron AD; Connor JM
Prenat Diagn; 2004 Oct; 24(10):774-80. PubMed ID: 15503268
[TBL] [Abstract][Full Text] [Related]
18. A unified approach to risk assessment for fetal aneuploidies.
Wright D; Wright A; Nicolaides KH
Ultrasound Obstet Gynecol; 2015 Jan; 45(1):48-54. PubMed ID: 25315809
[TBL] [Abstract][Full Text] [Related]
19. Comparison of serum markers in first-trimester down syndrome screening.
Canick JA; Lambert-Messerlian GM; Palomaki GE; Neveux LM; Malone FD; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Saade GR; Berkowitz RL; Dar P; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; D'Alton ME;
Obstet Gynecol; 2006 Nov; 108(5):1192-9. PubMed ID: 17077242
[TBL] [Abstract][Full Text] [Related]
20. First trimester maternal serum placental growth factor in trisomy 21 pregnancies.
Cowans NJ; Stamatopoulou A; Spencer K
Prenat Diagn; 2010 May; 30(5):449-53. PubMed ID: 20301202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
